Prestige Biopharma Limited

Single-Patient EA Policies/Criteria At Prestige Biopharma, we are committed to developing safe and effective drugs to improve the health and well-being of patients. We recognize that some patients may have serious or life-threatening conditions and are not able to participate in our clinical trials. For these patients, Expanded Access to investigational drugs may be an option. Currently, our investigational medicines are in early phase development, and we are not yet providing Expanded Access. We believe that participating in our clinical trials is the best way for patients to potentially access our investigational medicines prior to regulatory approval. We consider this approach to be the best opportunity to bring safe and effective treatments to patients. We encourage any person interested in gaining access to our investigational medicines to consult their physician regarding the possibility of participating in one of our clinical trials. Please review the information about Prestige Biopharma’s ongoing clinical trials found on this website as well as at https://clinicaltrials.gov/ . We wish to assure patients that we are constantly evaluating our policies and procedures. As such, Expanded Access may be reassessed in the future as our investigational medicines advance further in clinical trials and more data to support the safety and effectiveness becomes available. If you have any questions about our Expanded Access policy or our clinical trials, please contact us at info@prestigebio.com .